secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001736730-25-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 Q1 net loss $12.4M; Phase 1 UCD data Q4 2025; SYNGAP1 candidate nominated
-------------------------------------------------------------------------------

- Net loss of $12.4M for Q1 2025, flat YoY; cash, equivalents, and marketable securities $49.3M as of March 31, 2025.
- Phase 1 trial of CMP-CPS-001 for Urea Cycle Disorders ongoing; safety, PK, PD data expected Q4 2025.
- CTA submitted in Europe for Phase 1b clinical trial in female OTC heterozygotes.
- Nominated development candidate CMP-SYNGAP-01 for SYNGAP1-related disorders; GLP tox studies expected 2025.
- Milestone event achieved under Fulcrum license; eligible for $0.6M payment; potential up to $70M in milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000037/0001736730-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000037/camp-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer